GF Fund Management
CTNM icon

GF Fund Management’s Contineum Therapeutics CTNM Stock Holding History

GF Fund Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.45K Buy
704
+57
+9% +$849 ﹤0.01% 546
2026
Q2 		$10.6K Buy
647
+134
+26% +$1.76K ﹤0.01% 534
2026
Q1 		$6.7K Buy
513
+59
+13% +$791 ﹤0.01% 590
2025
Q4 		$5.19K Buy
+454
New +$5.18K ﹤0.01% 623

Other funds holding CTNM

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

GF Fund Management's CTNM Position: Q3 2026 in Review

GF Fund Management increased its Contineum Therapeutics (CTNM) stake by 8.8% in Q3 2026, buying an estimated $849 and bringing the position to 704 shares worth $9.45K. The position accounts for ﹤0.01% of the portfolio, ranked #546.

GF Fund Management first reported a position in CTNM in Q4 2025 and has held it in 4 quarters since. The position peaked at $10.6K in Q2 2026. 30 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • GF Fund Management held 704 shares of Contineum Therapeutics worth $9.45K as of Q3 2026.
  • GF Fund Management bought 57 Contineum Therapeutics shares in Q3 2026, an estimated $849.
  • Contineum Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #546 holding.
  • GF Fund Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • GF Fund Management's Contineum Therapeutics position peaked at $10.6K in Q2 2026.
  • 30 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.